Aurobindo Pharma Ltd’s consolidated net profit declined 11.4 per cent at ₹518 crore in the first quater ended June 30, 2017, compared with ₹585 crore in the corresponding quarter in the previous financial year.
The revenue of the Hyderabad-based company too, decreased 2.3 per cent to ₹3,678crore (₹3,766 crore)
“Òur key markets continue to maintain momentum despite headwinds. We believe the momentum to sustain going forward driven by changing product mix towards complex products,’’ N Govindarajan, Managing Director, said in a release here on Wednesday.
Aurobindo will remain focussed on strengthening its existing business and developing a differentiated and speciality driven product basket, he added.
The company has launched 15 products and three injectables during the quarter.
On Wednesday, the company’s scrip lost 5.84 per cent on the BSE to close at ₹684.15.